CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...
- Largest-ever HAE clinical trial meets on-treatment attack target – - NDA submission remains on track for first half 2024 – “We are excited to have reached the number of on-treatment attacks required ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results